Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abivax    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
22.7(c) 22.3(c) 22.3(c) 23.2(c) 23.75 Last
14 056 13 846 18 410 52 923 17 924 Volume
+1.79% -1.76% 0.00% +4.04% +2.37% Change
More quotes
Financials
Sales 2020 53,7 M 60,8 M 60,8 M
Net income 2020 -22,6 M -25,6 M -25,6 M
Net cash position 2020 48,2 M 54,6 M 54,6 M
P/E ratio 2020 6,30x
Yield 2020 -
Sales 2021 55,5 M 62,9 M 62,9 M
Net income 2021 31,2 M 35,3 M 35,3 M
Net Debt 2021 - - -
P/E ratio 2021 14,5x
Yield 2021 -
Capitalization 281 M 318 M 319 M
EV / Sales 2020 4,34x
Capi. / Sales 2021 5,07x
Nbr of Employees 26
Free-Float 47,4%
More Financials
Company
Abivax is a biotechnology company specializing in immune system targeting for viral diseases. The group operates three technological platforms: ?antiviral', ?immune stimulation' and ?polyclonal antibody' platform. The most advanced product, ABX464, is currently in Phase II clinical trial to assess its ability to become a functional healing element of HIV / AIDS. ABX464 is a new oral drug that inhibits viral... 
More about the company
Latest news on ABIVAX
07/02ABIVAX : treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
EQ
06/22ABIVAX : provides business update on most recent achievements and announces posi..
PU
06/22ABIVAX : provides business update on most recent achievements and announces posi..
EQ
06/15ABIVAX : Abivax receives ? 5m non-dilutive financing from Société Générale as St..
EQ
05/25ABIVAX : publishes universal registration document 2020 'Document d'Enregistreme..
EQ
05/25ABIVAX : announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVI..
EQ
05/20ABIVAX : postpones its Annual General Meeting to June 19, 2020
PU
05/20ABIVAX : postpones its Annual General Meeting to June 19, 2020
EQ
05/15ABIVAX : €36 million non-dilutive funding from bpifrance for abivax' abx464 covi..
PU
05/15ABIVAX : ?36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covi..
EQ
05/14ABIVAX : receives ANSM and Ethics Committee clearance to test its development ca..
EQ
05/14ABIVAX : ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted h..
EQ
04/29ABIVAX : postpones the publication of the yearly universal registration document..
EQ
03/17ABIVAX : 2019 Financial Results and Operations Update
AQ
03/16ABIVAX : 2019 Financial Results and Operations Update
EQ
More news
News in other languages on ABIVAX
07/02Les valeurs à suivre aujourd'hui à la Bourse de Paris Jeudi 2 juillet 2020
07/02ABIVAX : traite un premier patient avec son médicament contre le Covid-19
07/02ABIVAX : traite un premier patient dans l'essai de Phase 2b/3 d'ABX464 dans le C..
07/02ABIVAX : behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie..
07/02ABIVAX : treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
More news
Chart ABIVAX
Duration : Period :
Abivax Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 33,04 €
Last Close Price 23,20 €
Spread / Highest target 76,7%
Spread / Average Target 42,4%
Spread / Lowest Target -5,17%
EPS Revisions
Managers
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Philippe Pouletty Chairman
Didier Blondel Chief Financial Officer & Secretary
Didier Scherrer Vice President-Research & Development
Jean-Marc Steens Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX2.88%318
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344